GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 03, 2017 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017 at 8:30am PT in Dana Point, Calif. AGTC’s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.